Results 91 to 100 of about 3,401,781 (173)

Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. [PDF]

open access: yesClin Cancer Res, 2020
Faramand R   +25 more
europepmc   +1 more source

A Case of Cytokine Release Syndrome Induced by Avelumab and Axitinib Combination Therapy for Metastatic Renal Cell Carcinoma

open access: yes
Introduction Cytokine release syndrome (CRS) is a rare immune‐related adverse event of immune checkpoint inhibitors (ICIs). At present, its association with avelumab–axitinib therapy for renal cell carcinoma (RCC) has yet to be reported.
Hirokazu Kiuchi   +15 more
core   +1 more source

Mathematical modeling unveils the timeline of CAR-T cell therapy and macrophage-mediated cytokine release syndrome.

open access: yesPLoS Computational Biology
Chimeric antigen receptor (CAR)-T cell therapy holds significant potential for cancer treatment, although disease relapse and cytokine release syndrome (CRS) remain as frequent clinical challenges.
Daniela S Santurio   +3 more
doaj   +1 more source

Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma

open access: yesCase Reports in Hematology
Cytokine release syndrome (CRS) is a rare systemic inflammatory response that can be triggered by certain drugs and infections, commonly diagnosed at a disseminated stage, leading to poor prognosis. This has been well described following chimeric antigen
Erica Martel   +3 more
doaj   +1 more source

CAR T cell–derived TNF is an early determinant of cytokine release syndrome severity

open access: yes
Cytokine release syndrome (CRS) is a common and potentially severe toxicity of chimeric antigen receptor (CAR) T cell therapy, characterized by activation of the host myeloid compartment and systemic inflammation.
Theodoros Giavridis   +8 more
core   +1 more source

Cytokine release syndrome caused by immune checkpoint inhibitors: a case report and literature review

open access: yes
Immune checkpoint inhibitors (ICIs) have gained widespread application in the treatment of malignant tumors. Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by various factors, including infections and immunotherapy.
Xiuping Zhang   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy